Centrient Pharmaceuticals Adds API Capacity

Centrient Pharmaceuticals has started production at its new statins manufacturing unit at is existing Toansa site in India, the company announced in a June 21, 2021 press release. The new unit doubled the company’s statins production capacity for its sustainably manufactured atorvastatin and rosuvastatin APIs.

Demand for these statins has shown steady growth in the past years, according to the press release, partly due to replacement of older generation statins. The company says its dedicated statins production facility and backward integration into starting materials provides security of supply. The company says it has a reduced carbon footprint compared to traditional manufacturers and that its enzymatic route of synthesis and patented technology minimizes the use of solvents and generates less waste.

“The facility incorporates design features that allow further improvements in [good manufacturing practices] and energy utilization, and enable greater automation for improved process control,” said Jim McPherson, chief quality and technical operations officer, in the press release.

Construction began at the end of 2019 and commercial supplies from the new unit will start in mid-2021.

Source: Centrient